Immunocore Holdings (IMCR) Net Income towards Common Stockholders (2021 - 2026)
Immunocore Holdings (IMCR) posted quarterly Net Income towards Common Stockholders of $13.0 million for Q1 2026, up 160.25% year-on-year from $5.0 million in Q1 2025, and up 143.15% on a QoQ basis from -$30.1 million in Q4 2025.
Immunocore Holdings (IMCR) Net Income towards Common Stockholders (2021 - 2026) Analysis & Trends
Immunocore Holdings (IMCR) has reported Net Income towards Common Stockholders for 6 consecutive years, with $13.0 million the latest figure, recorded in Q1 2026.
- Quarterly Net Income towards Common Stockholders rose 160.25% year-over-year to $13.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$27.6 million (down 27.23% YoY) and the FY2025 annual result came in at -$35.5 million, up 30.48% from the prior year.
- Net Income towards Common Stockholders improved to $13.0 million in Q1 2026 per IMCR's latest filing, from -$30.1 million in the prior quarter.
- Over the last five years, Net Income towards Common Stockholders for IMCR reached as high as $13.0 million in Q1 2026 and fell as low as -$30.1 million in Q4 2025.
- A 5-year average of -$10.7 million and a median of -$14.6 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders soared 864.24% — and 2025, when it plunged 102.24%.
- Year by year, Net Income towards Common Stockholders stood at -$29.9 million in 2022, then surged by 33.95% to -$19.7 million in 2023, then slipped by 20.48% to -$23.8 million in 2024, then dropped by 26.46% to -$30.1 million in 2025, then jumped by 143.15% to $13.0 million in 2026.
- According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered $13.0 million, -$30.1 million, and -$196000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | -0.68 |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 472.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -453.82 Mn |
| 10 | Immunocore Holdings | 1.72 Bn | 878.48 Mn | 106.24 Mn | 12.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.97 Mn |
| Dec 31, 2025 | -30.06 Mn |
| Sep 30, 2025 | -196,000.00 |
| Jun 30, 2025 | -10.30 Mn |
| Mar 31, 2025 | 4.98 Mn |
| Dec 31, 2024 | -23.77 Mn |
| Sep 30, 2024 | 8.74 Mn |
| Jun 30, 2024 | -11.63 Mn |
| Mar 31, 2024 | -24.48 Mn |
| Dec 31, 2023 | -19.73 Mn |
| Sep 30, 2023 | 906,000.00 |
| Jun 30, 2023 | -17.62 Mn |
| Mar 31, 2023 | -19.46 Mn |
| Dec 31, 2022 | -29.87 Mn |
| Sep 30, 2022 | 7.34 Mn |
| Jun 30, 2022 | -19.69 Mn |
| Dec 31, 2021 | -53.10 Mn |
| Sep 30, 2021 | -41.54 Mn |